This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| pertuzumab | |
|---|---|
| Drug name | Pertuzumab |
| Tradename | Perjeta |
| Class | Monoclonal antibody |
| Legal status | Prescription only |
| Routes of administration | Intravenous |
pertuzumab
Pertuzumab is a recombinant humanized monoclonal antibody developed for targeted therapy of HER2-positive malignancies. It is principally used in combination regimens for breast cancer and has been evaluated in gastric and other solid tumors. The development, clinical testing, and regulatory review involved multiple pharmaceutical companies, cooperative groups, and international regulatory agencies.
Pertuzumab is used primarily for the treatment of HER2-positive metastatic and early-stage breast cancer in combination with agents such as trastuzumab and chemotherapy agents like docetaxel or paclitaxel. It has also been investigated for use in HER2-positive gastric cancer and explored in neoadjuvant and adjuvant settings, as well as in combination with targeted agents assessed in trials conducted by groups including the European Organisation for Research and Treatment of Cancer, National Cancer Institute, and industry sponsors such as Roche and Genentech.
Pertuzumab binds to the extracellular dimerization domain of the human epidermal growth factor receptor 2 protein found in HER2-positive tumor cells, inhibiting ligand-activated heterodimerization with receptors such as EGFR, HER3, and HER4. By preventing receptor dimerization it blocks downstream signaling pathways including the PI3K–AKT pathway and the RAS–RAF–MEK–ERK pathway, reducing cellular proliferation and survival. In combination with other HER2-directed agents like trastuzumab, pertuzumab enhances antibody-dependent cellular cytotoxicity mediated by immune effector cells such as natural killer cells and can produce complementary blockade of HER2 signaling.
Pertuzumab is an IgG1 kappa monoclonal antibody engineered from human and murine sequences with a high affinity for the HER2 dimerization domain. It exhibits linear pharmacokinetics at therapeutic doses with a distribution largely restricted to the vascular and interstitial compartments, and elimination mediated by proteolytic catabolism similar to other monoclonal antibodies. Pharmacokinetic evaluations have assessed parameters including clearance, volume of distribution, and half-life across populations studied in trials sponsored by organizations such as the Food and Drug Administration and regulatory bodies in the European Union.
Pertuzumab is administered by intravenous infusion, typically with an initial loading dose followed by maintenance doses every three weeks when used in standard regimens. Dosing regimens used in clinical trials and recommended in labeling often pair pertuzumab with intravenous trastuzumab and chemotherapy agents such as docetaxel, with infusion scheduling coordinated in oncology infusion suites at centers like comprehensive cancer centers affiliated with institutions such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Dose adjustments and treatment interruptions are guided by clinical evaluation and monitoring protocols described in product information reviewed by agencies including the European Medicines Agency.
Common adverse effects reported in clinical studies include infusion-related reactions, diarrhea, alopecia, neutropenia, and peripheral neuropathy associated with concurrent chemotherapy agents. Cardiotoxicity, manifested as left ventricular systolic dysfunction or congestive heart failure, has been observed particularly when combined with other HER2-targeted therapies, necessitating cardiac monitoring protocols similar to those endorsed by cardiology societies such as the American College of Cardiology and American Heart Association. Other serious adverse events reported across trials include febrile neutropenia and hypersensitivity reactions managed in oncology practice settings.
Pivotal randomized controlled trials led by cooperative groups and sponsor-led consortia compared pertuzumab-containing regimens against standard HER2-directed therapy, demonstrating improvements in progression-free survival and overall survival in populations with HER2-positive metastatic breast cancer. Landmark studies evaluated combinations such as pertuzumab plus trastuzumab and docetaxel in multicenter trials conducted across institutions in North America, Europe, and Asia, with outcomes reported at oncology meetings organized by groups such as the American Society of Clinical Oncology and European Society for Medical Oncology. Neoadjuvant trials assessed pathologic complete response rates in early-stage disease, influencing guideline recommendations from bodies like the National Comprehensive Cancer Network.
Regulatory approval for pertuzumab was granted following review by agencies including the Food and Drug Administration and the European Medicines Agency, with subsequent approvals in multiple jurisdictions worldwide. Availability and reimbursement decisions were influenced by health technology assessment bodies such as the National Institute for Health and Care Excellence and national payer systems in countries across North America, Europe, and Asia. Post-marketing surveillance and pharmacovigilance continue through partnerships among manufacturers, regulatory authorities, and international safety monitoring programs.